Nektar Therapeutics

Serina Therapeutics, Inc.

Nektar Therapeutics Al, Corporation

Shearwater Corporation

Debio Recherche Pharmaceutique S.a.

Shearwater Polymers, Inc.

Serina Therapeutics (al), Inc.

Other

The UAB Research Foundation (the University of Alabama at Birmingham)

Universities Space Research Association

St&e, Inc.

Stanley M. Klainer

Kisholoy Goswami

J. Milton Harris

J Milton Harris

Michael David Bentley

Antoni Kozlowski

Kunsang Yoon

Zhihao Fang

Xuan Zhao

Samuel P McManus

Tacey Viegas

Xiaoming Shen

Stephen A Charles

Francesco Maria Veronese

Oddone Schiavon

Rebecca Weimer

Paolo Caliceti

Lihong Guo

Randall W Moreadith

Jennifer A Riggs-Sauthier

Mei-chang Kuo

John S Patton

Wen Zhang

Chester Leach

Blaine Bueche

Kimberly Perkins

Michael Reif

Paola Caliceti

Samuel P Mcmanus

Robert S Snyder

Randall Moreadith

William Dudley Battle, Iii

Stanley M Klainer

James M Van Alstine

Steve Shafer

Blair Herren

Rainer Jordan

Robert J Sharpe

Rainer Jordon

Xuan Zhoa

Anna Mero

M R Sedaghat-Herati

Kusang Yoon

The present disclosure provides for polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer. Methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions comprising a POZ conjugate are also provided.

Polyoxazoline-drug conjugates with novel pharmacokinetic properties

Polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer and methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions including a POZ conjugate are also provided.

POZ-lipid conjugates and lipid nanoparticles (LNPs) including POZ-lipid conjugates used to facilitate delivery of an encapsulated payload. LNPs including POZ-lipid conjugates and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing a PEG-lipid.

Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same

The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.

Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.

Oligomer-corticosteroid conjugates

Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.

Polymer derivatives having particular atom arrangements

Methods for preparing water soluble, non-peptidic polymers carrying carboxyl functional groups, particularly carboxylic acid functionalized poly(ethylene glycol) (PEG) polymers are disclosed, as are the products of these methods. In general, an ester reagent R(C&#x2550;O)OR', wherein R&#x2032; is a tertiary group and R comprises a functional group X, is reacted with a water soluble, non-peptidic polymer POLY-Y, where Y is a functional group which reacts with X to form a covalent bond, to form a tertiary ester of the polymer, which is then treated with a strong base in aqueous solution, to form a carboxylate salt of the polymer. Typically, this carboxylate salt is then treated with an inorganic acid in aqueous solution, to convert the carboxylate salt to a carboxylic acid, thereby forming a carboxylic acid functionalized polymer.

Method of preparing carboxylic acid functionalized polymers

The present invention provides, among other things, compounds that include a water-soluble and non-peptidic polymer as well as a maleimidyl group. The compounds are useful as, among other things, polymeric reagents.

Methods for preparing functionalized polymers from polymer alcohols

The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.

Activated polyoxazolines and conjugates and compositions comprising the same

Method for preparing functionalized polymers from polymer alcohols

Growing community of inventors

Huntsville, AL, United States of America

J Milton Harris